A patient with recurrent multifocal GBM who received treatment with modified IL13Rα2-targeted CAR T cells had regression of all intracranial and spinal tumors, along with significant increases in the levels of cytokines C-X-C motif chemokine ligand 9 (CXCL9) and CXCL10, as well as immune cells in the cerebrospinal fluid [28]. Here, CXCL9 is linked to glioblastoma.